Major corporate mergers and strategic investments

Large-scale mergers and equity commitments reshape energy, healthcare and asset management sectors.

4 stories59 sourcesUpdated Oct 26, 2026

In this storyline:Range Resources Apollo Global Management Bon Secours Mercy Health

Major corporate mergers and strategic investments — Photo: Philip Samandar / Wikimedia Commons (Pexels)

Coverage momentum

total articles across this storyline · last 72h

185

articles now

370

peak · 2:00 PM

+446%

vs. first half

Oct 26, 11 AMdots mark key developments · hover for any hourOct 26, 3 PM

Key developments

Oct 26, 2026
EQT agreed to acquire Range Resources in an all-stock deal valued above $50B.
20 sources on this →
Oct 26, 2026
Bon Secours Mercy Health is in late-stage talks to buy Surgery Partners at $5.7B–$6B enterprise value.
13 sources on this →
Oct 26, 2026
Apollo takes a nearly 10% stake in Mubadala Capital with a $5B commitment.
23 sources on this →
Oct 26, 2026
Corxel and Amanat plan a merger yielding about $377M in gross proceeds for oral obesity drug CX11.
8 sources on this →

Coverage across the spectrum

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Stories in this storyline

Business

Apollo takes nearly 10% stake in Mubadala Capital with $5B commitment

Apollo takes a nearly 10% stake in Mubadala Capital as it and other investors commit $5 billion to the firm's strategies.

23 sources

Business

EQT, Range Resources Agree to $50B-Plus Merger

EQT agreed October 25, 2026 to buy Range Resources in an all-stock deal of about $12.8 billion equity, or more than $50 billion with debt, at 0.987 EQT shares per Range share.

Comments

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Bon Secours agrees to $5.7B Surgery Partners deal

Bon Secours Mercy Health is in late-stage talks to buy Surgery Partners at a $5.7B–$6B enterprise value; shares jumped after Oct. 26, 2026 reports.

13 sources

Business

Corxel, Amanat Plan $377M Obesity-Drug Merger

Corxel and Amanat plan a merger at a $200 million implied equity value expected to yield about $377 million in gross proceeds for oral obesity drug CX11.

8 sources